Author

Suppalux Limpiwattakee

Institutions: American Heart Association, University of California, Irvine, Mahidol University, University of California, Irvine Medical Center, Chulabhorn Hospital, Ramathibodi Hospital, Chulabhorn Royal Academy

Observed institutions: American Heart Association, University of California, Irvine, Mahidol University, University of California, Irvine Medical Center, Chulabhorn Hospital, Ramathibodi Hospital, Chulabhorn Royal Academy

OpenAlex ID: A5130611923

Survival of myelodysplastic syndrome patients after azacitidine therapy

2026 · Kanticha Thammagul, Suppalux Limpiwattakee, et al. · BMC Cancer · 1

Abstract 15003: The Cardiorenal Paradox: Life’s Essential 8 Health Behaviors, but Not Health Factors, Predict Cardiovascular Mortality in Advanced Chronic Kidney Disease

2026 · Issaree Bunyawannukul, Nathasith Tangprasittichok, et al. · Circulation

Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy

2026 · Kanticha Thammagul, Suppalux Limpiwattakee, et al. · BMC Cancer

Wcn26-5223 Development of Predictive Model for 30-day Mortality in Cancer Patients With Aki Requiring Rrt in Icu: a Single-centre Retrospective Cohort Study

2026 · Pratya Pumuthaivirat, Tanatorn Siripoon, et al. · Kidney International Reports

Wcn26-5508 Dual Renal Immune-related Adverse Events After Pembrolizumab: Acute Interstitial Nephritis and Type 4 Renal Tubular Acidosis—a Case Report

2026 · Pratya PumUthaivirat, Suppalux Limpiwattakee, et al. · Kidney International Reports

Works count: 5

Citation count: 1

H-index: 1

I10-index: